NextCure IncNASDAQ:NXTC
- LAST PRICE1.3100
- TODAY'S CHANGE (%)-0.0200 (-1.5038%)
- Bid / Lots1.2500/ 50
- Ask / Lots1.3200/ 15
- Open / Previous Close1.3400 / 1.3300
- Day Range
- 52 Week Range
- Volume134,167
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NXTC |
|---|---|---|
| 09:32 ET | 2204 | 1.33 |
| 09:34 ET | 465 | 1.3123 |
| 09:36 ET | 311 | 1.32 |
| 09:43 ET | 1589 | 1.3101 |
| 09:45 ET | 333 | 1.315 |
| 09:48 ET | 1000 | 1.3199 |
| 10:24 ET | 3719 | 1.34 |
| 11:00 ET | 500 | 1.33 |
| 11:06 ET | 100 | 1.3383 |
| 11:11 ET | 100 | 1.3387 |
| 11:13 ET | 1531 | 1.34 |
| 11:18 ET | 1900 | 1.3499 |
| 11:40 ET | 100 | 1.345 |
| 11:47 ET | 900 | 1.349 |
| 11:49 ET | 3639 | 1.3466 |
| 12:25 ET | 500 | 1.355 |
| 12:32 ET | 3338 | 1.358 |
| 12:57 ET | 2933 | 1.3201 |
| 01:12 ET | 176 | 1.3255 |
| 01:14 ET | 1100 | 1.35 |
| 01:28 ET | 758 | 1.33 |
| 01:37 ET | 5367 | 1.31 |
| 01:39 ET | 100 | 1.32 |
| 01:42 ET | 4700 | 1.28 |
| 01:44 ET | 8388 | 1.25 |
| 01:46 ET | 21200 | 1.24 |
| 02:08 ET | 1000 | 1.2801 |
| 02:11 ET | 193 | 1.3 |
| 02:15 ET | 2075 | 1.31 |
| 02:31 ET | 1085 | 1.295 |
| 03:02 ET | 2700 | 1.29 |
| 03:07 ET | 5000 | 1.3099 |
| 03:16 ET | 921 | 1.31 |
| 03:25 ET | 2959 | 1.33 |
| 03:30 ET | 100 | 1.3254 |
| 03:36 ET | 100 | 1.3 |
| 03:38 ET | 1500 | 1.29 |
| 03:39 ET | 3098 | 1.29 |
| 03:41 ET | 5515 | 1.31 |
| 03:45 ET | 3200 | 1.33 |
| 03:50 ET | 4660 | 1.325 |
| 03:54 ET | 8196 | 1.33 |
| 03:56 ET | 8923 | 1.3596 |
| 03:59 ET | 2166 | 1.31 |
Yesterday
Sep 12, 2023
Sep 7, 2023
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen, from 4:05PM ET on Thursday Sep 07, 2023 by Dow Jones
4:05PM ET on Thursday Sep 07, 2023 by Dow Jones
Sep 5, 2023
Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease, from 4:05PM ET on Tuesday Sep 05, 2023 by Dow Jones
4:05PM ET on Tuesday Sep 05, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NextCure Inc | 37.0M | -0.5x | --- |
Passage Bio Inc | 37.0M | -0.3x | --- |
NuCana PLC | 30.4M | -0.8x | --- |
IN8BIO, Inc. | 36.3M | -0.9x | --- |
Achilles Therapeutics PLC | 36.0M | -0.5x | --- |
Cognition Therapeutics Inc | 39.1M | -1.6x | --- |
Company Information
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO) platform, it is studying various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its product candidates include NC410, NC762 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1. NC762 is a monoclonal antibody that binds specifically to human B7 homolog 4 protein (B7-H4) a protein expressed on multiple tumor types. NC525 (LAIR-1 mAb) is a LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells (LSCs).
Contact Information
- Headquarters
- 9000 Virginia Manor Rd Ste 200BELTSVILLE, MD, United States 20705-4214
- Phone
- 240-399-4900
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Kabakoff
- President, Chief Executive Officer, Director
- Michael Richman
- Chief Financial Officer
- Steven Cobourn
- Chief Operating Officer
- Timothy Mayer
- Senior Vice President - Development and Manufacturing
- Sourav Kundu
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $37.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 27.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.13 |
EPS | $-2.53 |
Book Value | $6.03 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
